Laurus Labs enters into strategic partnership agreement with Global Fund

26 Mar 2019 Evaluate

Laurus Labs has entered into a strategic partnership agreement with Global Fund for a period of 3.5 years. Through this long term agreement, the company will have the volume commitments from the Global Fund for the treatment of HIV/AIDS.

Under this Partnership agreement, the company received and executed the order from Global Fund which would cater to the supplies of the high burden diseases countries in Sub Saharan African (SSA) region. This is the maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300/50mg (TLD) after the company received a tentative approval from USFDA in the month of February 2019.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

586.80 5.35 (0.92%)
18-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1748.60
Dr. Reddys Lab 1164.70
Cipla 1508.70
Lupin 2035.30
Zydus Lifesciences 903.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...